cyrilzakka/clinical-trials huggingface dataset:
Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke

The main goals of this project are to support the research training of undergraduate medical students at the University de Sherbrooke and promote planning of health services a better knowledge of the prevalence, social, and geographic distribution of public health issues in several regions in Quebec.

To meet the objectives of the project, a population-based prospective study linked to several regions in Quebec public health surveys is proposed.

Monitoring and data collection will be provided by 3rd year undergraduate medical students at University de Sherbrooke through telephone interviews.

The research themes will be proposed by various researchers affiliated with the University de Sherbrooke. They will be selected yearly by an internal scientific committee and included in the questionnaires administered by the students.


Eligibility Criteria:
Inclusion criteria:

* Participants will have been diagnosed with covid-19 between November 2020 and May 2021;
* Place of residence: province of Quebec.

Exclusion criteria :

- Unfit adults.
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.

Eligibility Criteria:
Inclusion Criteria:

- Postmenopausal women \>40 years of age experiencing a minimum of 7 to 8 moderate to severe hot flushes per day or 50 to 60 moderate to severe hot flushes per week

Exclusion Criteria:

* The usual exclusion criteria for hormone therapy apply
* Intake of medications other than hormones affecting hot flushes
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol (CBD).


Eligibility Criteria:
Key Inclusion Criteria:

* Subject has a clinical diagnosis of DS or LGS, where convulsive seizures (generalized tonic clonic seizures, tonic seizures, atonic seizures, tonic/atonic seizures, focal seizures with clear observable motor signs) are not completely controlled by current AEDs.
* All medications or interventions for epilepsy (including ketogenic diet \[KD\] and vagal nerve stimulation \[VNS\]) must be stable for at least 4 weeks prior to first ZX008 dose and are expected to remain stable throughout the study.
* Subjects must be taking a stable dose of CBD for at least 4 weeks prior to first ZX008 dose.
* Subject's source of CBD is expected to be consistent for at least 3 months during study participation.

Key Exclusion Criteria:

* Subject has current or past history of cardiovascular or cerebrovascular disease, myocardial infarction or stroke.
* Subject with current cardiac valvulopathy or pulmonary hypertension that the Investigator, parent/caregiver, Independent Cardiac Advisory Board, Independent Data and Safety Monitoring Committee, or sponsor deems clinically significant.
* Subject has a current or past history of glaucoma.
Front-of-Package Nutrition Labels

The goal of this study is to determine whether certain front-of-package food labeling systems improve the healthfulness of consumers' grocery selections. US adults who are their households' primary shoppers will complete a shopping task in a naturalistic online grocery store. They will be exposed to different front-of-package food labeling systems and asked to shop for groceries. The online store will record participants' selections. Participants will also be asked to complete survey measures.

This study aims to determine whether certain front-of-package food labeling systems improve the healthfulness of consumers' grocery selections. The survey research company Cloud Research will recruit a sample of approximately 5,610 US adults ages 18+ who read and speak English and who are their households' primary grocery shopper.

Participants will complete a between-subjects online randomized experiment. They will be randomized to 1 of 6 front-of-package labeling systems: 1) positive labels, 2) spectrum labels, 3) Food and Drug Administration (FDA) high in labels, 4) FDA traffic light labels, 5) FDA high in labels plus positive labels, or 6) FDA traffic light labels plus positive labels. Participants will complete a shopping task in a naturalistic online grocery store. Participants will be instructed to shop as they usually would for items in the following categories: non-alcoholic beverages (e.g., juice, coffee, tea, soda, sports drinks, water), breads and baked goods, breakfast cereals, soups, boxed and frozen meals, and snacks (e.g., chips, crackers, nuts, applesauce, dried fruit). They will be given a budget based on average spending in these categories in a large supermarket chain. The store will record participants' selections. After completing the shopping task, participants will complete an online survey.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 years or older
* Reside in the US
* Can read and speak English
* Are their household's primary shopper (do 50% or more of the grocery shopping for their household)

Exclusion Criteria:

* Under the age of 18
* Reside outside of the United States
* Unable to complete a survey in English
* Are not their household's primary shopper (do \<50% of the grocery shopping for their household)
The Oxylipin Response as a New PrEdictive Biomarker of Patient Responsiveness to Biotherapy in Rheumatoid Arthritis (OPERA)

OPERA aims to better understand and predict the responsiveness of rheumatoid arthrits (RA) patients to biological disease modifying anti-rheumatic drugs (bDMARDs).

Our objectives will be (i) to determine, at baseline, the differences of oxylipin response between responders vs non-responders to Anti-Tumor necrosis factor (Anti TNF) and (ii) to investigate the relationships between the oxylipin response, the polyunsatured fatty acid (PUFA) content of immune cells and the cytokine response.

30 RA patients starting an anti-TNF will be recruited.

Before and after 6-months of anti-TNF treatment, blood will be collected using the TruCulture system (2x 1ml in non-stimulated and Lipopolysaccharide (LPS)-stimulated TruCulture tubes) to measure Whole Blood Oxylipin Response (WBOR), cytokine response, PUFA cell content and gene expression under homeostatic and stimulated conditions (i.e. LPS).

At baseline and after 6 months of treatment, the rheumatologist will perform a clinical evaluation of their RA patients using Disease Activity Score using 28 joint-count (DAS28-CRP). Non-responders will be defined as RA patients failing to achieve good or moderate EULAR response after 6 month of anti-TNF treatment, discontinued the drug, initiated a new bDMARD, or increased dosage of oral corticosteroids greater than 10 mg/d at the second visit.

Eligibility Criteria:
Inclusion Criteria:

* Rheumatoid patient according to ACR-EULAR (American college of rheumatology-European League Against Rheumatism) 2010 criteria,
* Active disease defined by a DAS28-CRP\>3.2,
* Biological and targeted synthetic DMARDs naïve,
* Indication for treatment with anti-TNF
* Stable corticosteroid therapy ≤ 10 mg/day

Exclusion Criteria:

* Contra-indications to a biological DMARDS (current or recent cancer, active infection),
* Non-steroidal anti-inflammatory drugs (NSAIDs) treatment during the last 2 weeks before inclusion
Assessing Use Of Mifepristone After Progestin Priming For Use As "Missed Period Pills"

This study will assess the effectiveness and acceptability of a 3-day missed period pill regimen.

Missed period pills (MPPs) are medications used for uterine evacuation among women with late menses who have not confirmed pregnancy status. Provision of MPPs could expand reproductive service options for individuals in a variety of settings. This study will collect data on the efficacy, safety, and acceptability of a 3-day missed period pill regimen among individuals with missed menses of 1-10 days

Eligibility Criteria:
Inclusion Criteria:

* Age 18-49 years
* General good health
* Does not want to be pregnant
* History of regular monthly menstrual cycles (±3 days)
* Missed menses of 1 to 10 days as verified by report of last menstrual period
* Sexual activity in the past month
* Willing and able to sign consent forms
* Willing to return for a follow-up visit
* Willing to provide a urine sample at enrollment and at follow-up

Exclusion Criteria:

* Known allergies or contraindications to mifepristone
* Symptoms of or risk factors for ectopic pregnancy, such as vaginal bleeding or spotting within the past week; unilateral pelvic pain or significant bilateral pelvic pain within the past week; prior ectopic pregnancy; prior permanent contraception or other tubal surgery
* Current use of an IUD, contraceptive implant or injectable
Modulating Cortical Excitability to Improve Functional Movements in Individuals With Patellofemoral Pain

This study sought to investigate whether modulation of cortical excitability of the gluteal musculature, via tDCS paired with exercise, will reduce the amount the knee caves in during functional tasks in individuals with PFP. The objective is the explore if having tDCS target the area of the brain controlling hip muscles, when paired with exercise, will be more effective in reducing the amount the knee caves in for individuals with PFP versus those who receive exercise alone as their treatment. The aim is to contribute our findings to the growing knowledge in this area in order to help establish the possibility, and feasibility, of its use in clinical settings to strengthen traditional treatments for this patient population.


Eligibility Criteria:
Inclusion Criteria:

1. are between 18 and 45 years old
2. have had patellofemoral pain (PFP; kneecap pain) on one side for at least 3 months, and 3) the knee does cave in when performing functional movements.

Exclusion Criteria:

1. do not have pain coming from the kneecap during screening;
2. have a history of knee injury or surgery,
3. have a history of seizures and/or taking anti-seizure medication,
4. have an implanted device that interacts with electric current,
5. have a history of balance disorder,
6. currently are pregnant or think they may be pregnant.
Isokinetic Training Combined with Blood Flow Restriction on Muscle Strength and Endurance

Evidence regarding the effectiveness of blood flow restriction during isokinetic exercises is insufficient. When the literature is reviewed, it is seen that there are very few studies investigating the effect of isokinetic training program with blood flow restriction on muscle strength and endurance in healthy athletes. In line with this information, the aim of this study was to investigate the effect of an 8-week isokinetic training program combined with blood flow restriction on knee flexor and extensor maximal muscle strength and endurance in runners.

The purpose of this study is to investigate the effect of lower extremity isokinetic training combined with blood flow restriction (BFR) on knee flexor and extensor muscle strength and endurance in runners. A total of 42 runners were randomly assigned to either the isokinetic training group with blood flow restriction (BFR Group; n= 21) or the isokinetic training group without blood flow restriction (Control Group; n= 21). For the BFR, the occlusion pressure was set to 80% of arterial occlusion pressure as determined. The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions. The muscle strength and endurance were evaluated before and after the training program using an isokinetic dynamometer.

Eligibility Criteria:
Inclusion Criteria: the absence of heart disease, arterial hypertension, diabetes mellitus or any musculoskeletal condition of the lower extremities that precluded participation in the recommended training protocols and testing, no use of any dietary supplements during the study and for at least 2 months prior to the study and running more than 20 kilometers per week.

-

Exclusion Criteria: Age \<20 or \>40, history of cardiac disease, history of heart failure, history of coronary artery disease, history of peripheral artery disease, presence/history of varicose veins, history of hypertension, history of diabetes mellitus, history of pulmonary disease, history of pulmonary embolism, history of hematological disease, history of previous deep vein thrombosis, pregnancy, use of oral contraceptives, use of anticoagulants, history of previous surgery in the lower extremity, body mass index \>25, history of cancer, presence of lymphedema, history of lymphadenectomy, history of trauma in the lower extremity within the last 6 months or 1 year.

-
Impact of the Depth of Neuromuscular Blockade on Respiratory Mechanics in Moderate to Severe ARDS Patients

Neuromuscular blockade (NMB) is proposed in patients with moderate to severe acute respiratory distress syndrome (ARDS). The supposed benefit of these muscle relaxants could be partly linked to their effects on respiratory mechanics by reducing ventilator induced lung injuries (VILI), especially the so called atelectrauma. Although its monitoring is recommended in clinical practice, data about the depth of NMB necessary for an effective relaxation of the thoracic and diaphragmatic muscles and, therefore, the reduction of the chest wall elastance, are scarce. The investigators hypothesised that complete versus partial NMB can modify respiratory mechanics and its partitioning.

The investigators conducted a prospective study to compare the respiratory mechanics of patients with moderate to severe ARDS according to the NMB depth, using an oesophageal pressure catheter (NutriVent®, Sidam) for transpulmonary pressure (PL) assessment, and facial train of four (TOF) for neuromuscular blockade monitoring. The oesophageal balloon was calibrated according to the method recently described to estimate the individual target volume which is assumed to be more adequate. Each patient was analysed at two different times: deep NMB (TOF = 0) and intermediate to light NMB (TOF \> 0). The mechanical ventilation parameters were identical for these two measurements. The primary endpoint was the proportion of patients with expiratory transpulmonary pressure (PLexp) greater than or equal to 0 according to the NMB level, in order to assess the risk of region-dependent atelectasis and alveolar opening/closing injury (atelectrauma). Secondary endpoints included: the impact of the depth of NMB on other partition parameters of respiratory mechanics, and the variability of results according to the type of oesophageal balloon calibration.

Eligibility Criteria:
Inclusion Criteria:

* Moderate to severe ARDS patients with PaO2/FiO2 ratio \< 150 mmHg
* Mechanical ventilation, deep sedation and neuromuscular blockade with continuous infusion of cisatracurium for more than 24 hours
* Presence of an oesophageal catheter
* Written informed consent

Exclusion Criteria:

* contraindication of oesophageal catheter
The Comparison With Clinical Impacts on Functional Capacity and Symptom Improvement According to the Rhythm Control in Patients With Heart Failure and Recent Onset Atrial Fibrillation

Prospective randomized (rhythm control or rate control in heart failure patients with new onset atrial fibrillation) Objective of study 1. To analyze long term outcome of patients with heart failure with new onset atrial fibrillation according to the rhythm control 2. To analyze remodeling of atrium and ventricle by the new onset AF in heart failure patients 3. To analyze the change of LV function and functional capacity according to the rhythm in patients with HF and new onset AF


Eligibility Criteria:
Inclusion Criteria:

1. Patients with Heart failure and Atrial fibrillation within 1year (20\~80 years old)
2. LA diameter \< 5mm
3. LVEF 20\~49%
4. patients possible to anticoagulation and anti arrhythmic drug
5. Expected survival \>1yr

Exclusion Criteria:

1. Impossible to anticoagulation or anti arrhythmic drug
2. valvular atrial fibrillation ( Mitral valve stenosis, Mitral valve plasty, valve replacement)
3. LV ejection fraction \< 20%
4. Structural cardiac disease
5. Catheter ablation history for AF, maze surgery
6. patient with severe medical disease
7. Impossible to anticoagulation or anti arrhythmic drug
Bilingual Family Literacy Program Pilot

This study will examine the feasibility of implementing a virtual bilingual health-focused family literacy program.

"Ready and Healthy for Kindergarten" is a bilingual family literacy program that uses anticipatory guidance on important health routines to introduce critical language and literacy skills to young Latino children entering Kindergarten and their families.

The objectives of this study are 1) To assess the feasibility of implementing the bilingual family literacy program online via video conference by collecting information on family attendance and participation, 2) To examine the acceptability of the program, and 3) To explore preliminary effects of the program on the family health and language routines as well as child language and literacy skill acquisition.

Eligibility Criteria:
Inclusion Criteria:

* Preferred language either Spanish or bilingual (English and Spanish)
* Parent or legal guardian of the child
* Parent Age ≥ 18

Exclusion Criteria:

* Children not entering Kindergarten.
Effect of Insulin Therapy by Ultrasonography in Wound Healing of Chronic Diabetic Patients

The main aim of the study is to determine the effect of transdermal application of insulin therapy by phonophoresis in wound healing in diabetic patients the main question of the study: is insulin phonophoresis is effective in accelerating healing in patients with diabetes mellites? 40 patients will be randomly assigned to two groups group A will receive insulin phonophoresis plus hyper polarized laser therapy and standard wound cleaning and dressing three times weekly over four weeks.

Group B will receive hyper polarized laser therapy and standard wound cleaning and dressing three times weekly over four weeks.

DIMST scale ( as an acronym from the initial domains of depth, maceration, inflammation/infection, size, tissue type of the wound bed, type of wound edge, and tunneling/undermining) will be used for assessment.

MANOVA will be used for statistical analysis between group comparison

Eligibility Criteria:
Inclusion Criteria:

* patients will be included if they are free from any pathological condition like limb infection, local or proximate malignancy, and anti-coagulated patients.

Exclusion Criteria:

patients will be excluded if they have any pathological condition like limb infection, local or proximate malignancy, and anti-coagulated patients.
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

The primary objectives of this study are to:

* Assess the long-term safety of KRN23 subcutaneous (SC) administration in adult subjects with XLH
* Assess the proportion of subjects achieving serum phosphorus levels in the normal range (2.5-4.5 mg/dL) with long-term administration of KRN23
* Assess long-term pharmacodynamics (PD) of KRN23 as measured by changes in the following: serum intact parathyroid hormone (iPTH); serum and urinary phosphorus; ratio of renal tubular maximum phosphate reabsorption rate to glomerular filtration rate (TmP/GFR) and tubular reabsorption of phosphate (TRP); serum 1,25-dihydroxy vitamin D (1,25\[OH\]2D); serum fibroblast growth factor 23 (FGF23); bone biomarkers: serum alkaline phosphatase (ALP), bone-specific ALP (BALP), carboxy terminal crosslinked telopeptide of type I collagen (CTx), and procollagen type 1 N-terminal propeptide (P1NP)
* Assess long-term immunogenicity of KRN23 as measured by presence of anti-KRN23 antibody (ADA)


Eligibility Criteria:
Inclusion Criteria:

1. Have participated in Kyowa Hakko Kirin Pharma, Inc.'s KRN23-INT-001 (NCT01340482) or KRN23-INT-002 (NCT01571596) studies (received at least 2 doses of KRN23)
2. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min or eGFR of 45 to \< 60 mL/min at Screening with confirmation that the renal insufficiency was not due to nephrocalcinosis.
3. Sexually active subjects must be willing to use an acceptable method of contraception (e.g., double barrier method) while participating in the study and for 30 days after receiving the last dose of KRN23.

Exclusion Criteria:

1. Subject experienced a safety-related event in the KRN23-INT-001 or KRN23-INT-002 study that, in the opinion of the investigator and sponsor, precludes resuming KRN23 treatment.
2. Presence of nephrocalcinosis on renal ultrasound that, in the opinion of the investigator and sponsor, precludes resuming KRN23 treatment.
3. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
4. Participation in an investigational drug or device trial within 30 days of enrollment (other than KRN23-INT-001 or KRN23-INT-002).
5. Use of a pharmacologic vitamin D metabolite or analog (e.g., calcitriol, doxercalciferol, and paricalcitol), phosphate, or aluminum hydroxide antacids (e.g., Maalox® and Mylanta®) within 21 days prior to Screening or during the study.
6. Use of medication to suppress parathyroid hormone (PTH) (e.g., Sensipar®, cinacalcet, calcimimetics) within 2 months prior to Screening.
Results of a Mobile Unicompartimental Knee Prosthesis

The unicompartmental knee prosthesis has become a routine procedure. Survival rate of over 90% after 10 years are generally reported. However, complications and reoperation may still occur for many reasons, and some of them may be related to component design: loosening (tibial above), polyethylene wear, knee stiffness, ligamentous instability, etc ... . Therefore, new designs can, at least in theory, improve the results of conventional models.

In this study, the investigators want to compare retrospectively data concerning survival rates of patients wearing unicompartmental knee prosthesis with mobile plate for over 10 years, with the ones published in the literature for conventional fixed-bearing prostheses and mobile-bearing prostheses


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years
* Patients wearing unicompartmental knee prosthesis with mobile plate for over 10 years

Exclusion Criteria:

* Patients under 18 years